NEW YORK and ATLANTA, May 15 /PRNewswire/ -- Paul Capital Healthcare today announced that New York-based partner, John Leone, will participate in a panel on non-traditional forms of financing at the 2009 BIO International Convention. Designed to familiarize participants with how to evaluate non-dilutive financing options that can meet the needs of companies at diverse stages of development, the panel, "Non-dilutive and Other Non-traditional Forms of Financing," is scheduled for 2:00-3:30 pm ET, Wednesday, May 20th. The panel, presented as part of the Biotechnology Industry Organization International Convention, will be held at the Georgia World Congress Center in Atlanta.
Relevant at a time when IPOs are hard to execute and equity valuations uncertain, this panel will explore various models for obtaining capital for product development other than through equity finance. Mr. Leone will provide an overview and case studies of royalty and structured revenue financing transactions, as well as discuss how these financing strategies are critical for biotechnology companies in the months ahead.
"In the current financial environment, obtaining capital from traditional equity and debt markets is exceedingly difficult for small- and mid-size biotechnology companies," said John Leone, partner at Paul Capital Healthcare. "The total value of biotechnology financing transactions in 2008 was down 50% compared with 2007, and data from the first quarter of 2009 suggest that the environment will remain challenging over the near term. At the same time, increasing development costs coupled with favorable healthcare market dynamics continue to fuel the funding needs of biotechnology companies. Fortunately, there are a variety of alternative financing strategies available to companies across all stages of development, and this panel will provide insight into viable and available methods for accessing capital from investors who are actually doing deals in today's market. Both royalty monetization and revenue interest financing transactions, which are non-dilutive and can be tailored to meet the needs of individual companies, will be discussed."
About Paul Capital Healthcare and Paul Capital Partners
Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.6 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $965 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $6.6 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.
Contact Information: Paul Capital Healthcare John Leone, Partner Tel: (646) 264-1144 Email: email@example.com Lazar Partners Stephanie Seiler Tel: (206) 713-0124 Email: firstname.lastname@example.org Susan Rood Tel: (212) 843-0210 Email: email@example.com
|SOURCE Paul Capital Healthcare|
Copyright©2009 PR Newswire.
All rights reserved